IP Library Granted Patent US 12,138,488
Granted Patent B2
US 12,138,488 · App. 18/540,651 · Granted Nov 12, 2024

Methods of treating cancer with drugs

Inventors: Vijay Agarwal (New York, NY); Braden Eliason (Minneapolis, MN); Jeremy Ling (Mendota Heights, MN)
Assignee: Alpheus Medical, Inc.
A61N7/00A61F7/0085A61K9/0053A61K31/197A61K41/0033A61K41/0061A61M21/02A61P35/00B06B1/0207B06B1/0622A61B2017/00084A61B2017/320069A61B2018/00023A61B2018/00446A61F2007/0056A61F2007/0096A61F2007/0288A61M2021/0027A61M2021/005A61N2007/003A61N2007/006A61N2007/0073A61N2007/0078A61N2007/0082A61N2007/0095B06B2201/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,138,488
App. No.
18/540,651
Granted
Nov 12, 2024
Kind
B2
Abstract

Methods of treating tumors by administering compounds to a patient are provided. Compounds such as drugs, may be administered to the patient orally, by injection, intravenously, or topically, which then accumulate as compounds such as a protoporphyrin compound in tumor cells. After such accumulation, such compounds are then activated in various aspects to treat tumors cells, thereby treating cancer. Cancers such as glioblastoma may be treated.

Claims (31)

1. A non-invasive method of treating cancer with a drug, comprising:

administering a drug to a patient with cancer cells,

wherein said drug results in increased production of a porphyrin compound,

wherein said porphyrin compound is accumulated in said cancer cells, activating said porphyrin compound via ultrasound,

wherein said ultrasound is defocused or planar,

wherein said activating said porphyrin compound results in said porphyrin compound causing apoptosis of said cancer cells; and

cooling said patient by circulating a cooling fluid.

2. The method of claim 1 , wherein said increased production of said porphyrin compound is via a heme biosynthesis pathway, wherein said porphyrin compound is accumulated in said cancer cells via a reduced expression of ferrochelatase.

3. The method of claim 1 , wherein said porphyrin compound is accumulated in mitochondria in said cancer cells.

4. The method of claim 1 , wherein activating said porphyrin compound via ultrasound comprises a chemical phenomenon.

5. The method of claim 1 , wherein activating said porphyrin compound via ultrasound comprises a mechanical phenomenon.

6. The method of claim 1 , wherein activating said porphyrin compound via ultrasound comprises a non-ablative thermal phenomenon.

7. The method of claim 1 , wherein said porphyrin compound converts dissolved molecular oxygen into a reactive oxygen species (ROS) that initiates a cytotoxic effect in said cancer cells.

8. The method of claim 1 , wherein said administering said drug to said patient comprises an oral administration, wherein said drug comprises aminolevulinic acid (ALA).

9. The method of claim 1 , wherein said administering said drug to said patient comprises an injection or an intravenous administration.

10. The method of claim 1 , wherein said porphyrin compound is accumulated in a glioblastoma multiforme (GBM) in a brain.

11. The method of claim 1 , wherein said porphyrin compound is accumulated in said cancer cells in a tissue selected from the group consisting of: a brain, a lung, a breast, a liver, a pancreas, an intestine, a stomach, a rectum, a vagina, testes, a prostate, and a cervix.

12. The method of claim 1 , wherein said drug comprises 5-aminolevulinic acid and wherein said porphyrin compound comprises protoporphyrin IX.

13. The method of claim 1 , wherein said activating said porphyrin compound produces a non-ablative treatment with a temporal average intensity without increasing a temperature of a tissue in a treatment region above 42° C.

14. A non-invasive method of treating cancer with a drug, comprising:

administering a drug to a patient with cancer cells,

wherein said drug results in increased production of a porphyrin compound, activating said porphyrin compound with a sonodynamic treatment via ultrasound,

wherein said ultrasound is defocused or planar,

wherein said activating said porphyrin compound results in said porphyrin compound causing necrosis of said cancer cells; and

cooling said patient by circulating a cooling fluid.

15. The method of claim 14 , wherein said increased production of porphyrin compound is via a heme biosynthesis pathway, wherein said porphyrin compound is accumulated in said cancer cells via a reduced expression of ferrochelatase.

16. The method of claim 14 , wherein activating said porphyrin compound via ultrasound comprises a chemical phenomenon.

17. The method of claim 14 , wherein activating said porphyrin compound comprises cavitation induced via said ultrasound.

18. The method of claim 14 , wherein said drug comprises 5-aminolevulinic acid and wherein said porphyrin compound comprises protoporphyrin IX.

19. The method of claim 14 , wherein said administering said drug to said patient comprises an oral administration, wherein said drug comprises aminolevulinic acid (ALA).

20. The method of claim 14 , wherein said administering said drug to said patient comprises an injection or an intravenous administration, wherein said drug comprises aminolevulinic acid (ALA).

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 5, 2024
From: AGARWAL, VIJAY; ELIASON, BRADEN; LING, JEREMY
To: CRANIOVATION, INC.
Reel/Frame 067022/0896 →
CHANGE OF ADDRESS Recorded Apr 5, 2024
From: ALPHEUS MEDICAL, INC.
To: ALPHEUS MEDICAL, INC.
Reel/Frame 067025/0971 →
CHANGE OF NAME Recorded Apr 5, 2024
From: CRANIOVATION, INC.
To: ALPHEUS MEDICAL, INC.
Reel/Frame 067026/0292 →
Continuity (6)
Continuation 18125959 · Mar 24, 2023
Continuation 17733868 · Apr 29, 2022
Continuation 17399996 · Aug 11, 2021
Continuation PCTUS2020017983 · Feb 12, 2020
Provisional Application 62805186 · Feb 13, 2019
Related Publication 20240108917A1 · Apr 4, 2024